BR0312871A - análogos de grelina, método para identificação de um composto capaz de se ligar a um receptor de ghs e usos de tais análogos - Google Patents

análogos de grelina, método para identificação de um composto capaz de se ligar a um receptor de ghs e usos de tais análogos

Info

Publication number
BR0312871A
BR0312871A BRPI0312871-7A BR0312871A BR0312871A BR 0312871 A BR0312871 A BR 0312871A BR 0312871 A BR0312871 A BR 0312871A BR 0312871 A BR0312871 A BR 0312871A
Authority
BR
Brazil
Prior art keywords
analogs
identifying
binding
compound capable
ghs receptor
Prior art date
Application number
BRPI0312871-7A
Other languages
English (en)
Inventor
Zheng Xin Dong
Yeelana Shen
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of BR0312871A publication Critical patent/BR0312871A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

ANáOGOS DE GRELINA, MéTODO PARA IDENTIFICAçãO DE UM COMPOSTO CAPAZ DE SE LIGAR A UM RECEPTOR DE GHS E USOS DE TAIS ANáLOGOS. A invenção compreende análogos de peptidil que possuem atividade de grelina agonista ou antagonista, junto com seus usos terapêuticos e não-terapêuticos.
BRPI0312871-7A 2002-07-23 2003-07-23 análogos de grelina, método para identificação de um composto capaz de se ligar a um receptor de ghs e usos de tais análogos BR0312871A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39783402P 2002-07-23 2002-07-23
US42748802P 2002-11-19 2002-11-19
PCT/US2003/022925 WO2004009616A2 (en) 2002-07-23 2003-07-23 Ghrelin analogs

Publications (1)

Publication Number Publication Date
BR0312871A true BR0312871A (pt) 2007-07-10

Family

ID=34278194

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312871-7A BR0312871A (pt) 2002-07-23 2003-07-23 análogos de grelina, método para identificação de um composto capaz de se ligar a um receptor de ghs e usos de tais análogos

Country Status (18)

Country Link
US (3) US7589058B2 (pt)
EP (2) EP1578778B1 (pt)
JP (2) JP2006515271A (pt)
KR (1) KR101065471B1 (pt)
AR (2) AR040955A1 (pt)
AT (1) ATE496940T1 (pt)
AU (1) AU2003254119B2 (pt)
BR (1) BR0312871A (pt)
CA (1) CA2491946C (pt)
DE (1) DE60335913D1 (pt)
IL (1) IL166170A (pt)
MX (1) MXPA05000908A (pt)
NO (1) NO334857B1 (pt)
PL (1) PL212106B1 (pt)
PT (1) PT1578778E (pt)
RU (3) RU2315059C2 (pt)
TW (1) TWI325003B (pt)
WO (1) WO2004009616A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496940T1 (de) 2002-07-23 2011-02-15 Ipsen Pharma Ghrelin-analoga
EP1750745A1 (en) * 2004-05-11 2007-02-14 The United States of America, represented by the Secretary, Department of Health and Human Services Methods of inhibiting proinflammatory cytokine expression using ghrelin
CA2625920C (en) * 2005-09-28 2014-12-23 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogs of ghrelin
CN101287464A (zh) * 2005-09-29 2008-10-15 科学研究和应用咨询股份公司 用于刺激胃肠运动性的组合物和方法
US8992928B2 (en) * 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
EP2012809B1 (en) * 2006-03-10 2013-05-22 Ipsen Pharma Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
NZ571183A (en) * 2006-03-13 2010-09-30 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
AU2007300526B2 (en) 2006-09-27 2011-07-21 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the N-terminal
WO2008067831A2 (en) * 2006-12-05 2008-06-12 Charite Universitätsmedizin - Berlin Use of ghrelin, an analogue thereof or a pharmaceutically acceptable salt thereof
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US8883721B2 (en) * 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
CN102812037A (zh) 2009-10-30 2012-12-05 特兰齐姆制药公司 大环生长素释放肽受体拮抗剂和反向激动剂及其使用方法
AU2011268256B8 (en) * 2010-06-16 2016-12-22 Mcgill University Growth hormone secretatogue receptor antagonists and uses thereof
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
TW201336864A (zh) * 2012-02-03 2013-09-16 Zealand Pharma As 胃飢餓素（ｇｈｒｅｌｉｎ）類似物
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN108029863B (zh) * 2018-01-19 2021-07-27 广州英赛特生物技术有限公司 丁酰甘氨酸及其衍生物在制备动物饲料添加剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8821785D0 (en) * 1988-09-16 1988-10-19 Nycomed As Peptide compounds
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
ES2308779T3 (es) 1995-07-26 2008-12-01 Astrazeneca Ab Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas.
ATE279440T1 (de) 1995-12-13 2004-10-15 Merck & Co Inc Wachstumshormonsekretionsförderer rezeptorfamilie
RU2208015C2 (ru) * 1998-12-07 2003-07-10 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас Аналоги гпп-1
ATE366813T1 (de) 1999-07-23 2007-08-15 Kenji Kangawa Neue peptide
EP1353683A4 (en) 2000-05-30 2004-05-12 Merck & Co Inc ANALOGS BY GHRELIN
US20020187938A1 (en) 2000-07-24 2002-12-12 Romano Deghenghi Ghrelin antagonists
CA2443147A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
ATE496940T1 (de) 2002-07-23 2011-02-15 Ipsen Pharma Ghrelin-analoga

Also Published As

Publication number Publication date
TW200403253A (en) 2004-03-01
EP1578778A4 (en) 2007-02-28
PL212106B1 (pl) 2012-08-31
IL166170A (en) 2011-01-31
AR073099A2 (es) 2010-10-13
RU2007124275A (ru) 2009-01-10
KR20050026503A (ko) 2005-03-15
CA2491946A1 (en) 2004-01-29
MXPA05000908A (es) 2005-07-22
JP2006515271A (ja) 2006-05-25
US9133261B2 (en) 2015-09-15
EP1578778A2 (en) 2005-09-28
US20050272648A1 (en) 2005-12-08
NO334857B1 (no) 2014-06-23
EP1578778B1 (en) 2011-01-26
NO20050083L (no) 2005-03-23
KR101065471B1 (ko) 2011-09-16
RU2315059C2 (ru) 2008-01-20
IL166170A0 (en) 2006-01-15
AU2003254119A1 (en) 2004-02-09
JP2009161546A (ja) 2009-07-23
EP2258381A3 (en) 2011-11-02
CA2491946C (en) 2013-05-28
US8633151B2 (en) 2014-01-21
AU2003254119B2 (en) 2007-11-29
RU2009127162A (ru) 2011-01-20
US20100069299A1 (en) 2010-03-18
WO2004009616A3 (en) 2006-02-09
DE60335913D1 (de) 2011-03-10
PL377075A1 (pl) 2006-01-23
AR040955A1 (es) 2005-04-27
TWI325003B (en) 2010-05-21
ATE496940T1 (de) 2011-02-15
WO2004009616A2 (en) 2004-01-29
RU2373220C2 (ru) 2009-11-20
PT1578778E (pt) 2011-03-07
EP2258381A2 (en) 2010-12-08
US20140135260A1 (en) 2014-05-15
RU2005104841A (ru) 2005-09-10
US7589058B2 (en) 2009-09-15

Similar Documents

Publication Publication Date Title
BR0312871A (pt) análogos de grelina, método para identificação de um composto capaz de se ligar a um receptor de ghs e usos de tais análogos
AU3652102A (en) Compounds and their uses
WO2003029262A3 (en) The human mob-5 (il-24) receptors and uses thereof
AU4968397A (en) Antipruritic
SV2005002148A (es) "compuestos moduladores de la actividad c-kit y usos de los mismos"
RS63204A (en) Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
DK1213969T4 (da) Metode til overtrækning af levnedsmidler under anvendelse af hydrogeneret isomaltuloseblanding
GB0130347D0 (en) Compounds
HK1035377A1 (en) Receptor based antagonists and methods of making and using
UY28598A1 (es) Antagonistas de receptores de acetilcolina muscarinicos
MA29088B1 (fr) Composes d'indazole-carboxamide.
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
BR0017311A (pt) Método a ser realizado em um sistema de comunicação, sistema de comunicação, e, elemento de rede
PL331634A1 (en) Bicyclic derivatives of pyrimidine and their application as anticoagulants
BRPI0515319A (pt) análogos de quinolona
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
PT1473036E (pt) Solvato de hemitartarato de zolpidem
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
DK1096936T3 (da) Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister
DK1141286T3 (da) Kæde af cytokinreceptorer
DK1313485T3 (da) Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
BR9809848A (pt) Composição
WO2002056010A3 (en) Methods for the treatment of ibs

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 4A., 5A., 6A., E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.